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INTRODUCTION
Esophageal cancer is the sixth most common cause of cancer related mortality in men, with 3-fold higher rates in men than women (1, 2) . Of the two main histological subtypes (adenocarcinoma and squamous cell carcinoma), the incidence of esophageal adenocarcinoma (EAC) has been rising continuously in Western countries, and accounts for the majority of cases (3) (4) (5) . Despite aggressive treatment, EAC has a 5-year survival of less than 20% (6) . EAC is thought to develop from the metaplastic condition Barrett's esophagus (BE) as a consequence of gastroesophageal reflux disease (GERD) through a metaplasia-dysplasia-adenocarcinoma sequence ( Figure 1A ) (7) (8) (9) .
Currently, BE patients usually undergo endoscopy-biopsy surveillance with the degree of dysplasia assessed by histopathology as a biomarker to monitor risk of neoplastic progression (10) .
Patients diagnosed with high-grade dysplasia (BE-HGD) are treated with endoscopic mucosal resection, radiofrequency ablation or surgery, in an attempt to halt further disease progression (10) (11) (12) . The significant cost of endoscopy plus the low annual progression rate to HGD or EAC means that the cost-effectiveness of endoscopic surveillance is questioned at the population level (13) (14) (15) (16) .
Furthermore the evaluation of dysplasia in tissue biopsies by histopathology is prone to interobserver variability and sampling error (17). A less costly and minimally invasive diagnostic procedure is needed for cost-effective screening and surveillance of at-risk populations (18, 19) .
We envisage that a blood test which can reliably discriminate BE-HGD and EAC from BE, GERD and healthy patients could be used to pre-select the patients for endoscopic examination, while reducing unnecessary endoscopy for the majority of patients in a surveillance program.
As the first step to developing blood-based EAC diagnostic test, we focused on differential lectin binding of serum glycoproteins during EAC pathogenesis. We established a new by guest on November 18, 2018 http://www.mcponline.org/ Downloaded from glycoprotein biomarker pipeline which couples lectin-based glycoprotein isolation with state-ofthe-art discovery and targeted proteomics (20) (21) (22) . We then applied it to identify and verify changes in lectin binding profile of serum glycoproteins between healthy, BE and EAC patients (22) . Here, we report results from validation in independent cohorts, and evaluation of biomarker panels for surveillance of BE patients.
EXPERIMENTAL PROCEDURES

Clinical cohorts
Ethical approval was obtained from all participating institutions, and all patients provided informed consent to participate in the studies. We investigated two independent cohorts recruited treatments. These patients were confirmed to have no Barrett's mucosa by histology at the time of serum collection, however they may have submucosal disease, hence the normal groups will be now onwards called non-specialized epithelium [NSE, epithelium without Barrett's mucosa]. The Ochsner cohort comprised of 14 NSE, 13 BE, 3 BE-ID (Barrett's mucosa which is indefinite for dysplasia), 2 BE-LGD, 7 BE-HGD, and 10 EAC patients.
Similar procedure of serum collection was followed across all sites. Briefly, 10 mL of blood was collected by trained phlebotomists into Vacutainer red top collection tubes [Becton Dickinson (BD)]. Once in the lab, the blood was allowed to coagulate at room temperature for a minimum of 20 minutes. The tubes were centrifuged at 3000 RPM (Beckman CS-6R) for 10 minutes at 22°C (brake off) making sure that all blood was separated. Using sterile pipette, the serum was removed, aliquots were prepared and stored at -80°C. Serum samples were shipped to the Translational Research Institute, Brisbane on dry ice for this study. The clinical diagnosis linked to the sample was based on histological examination of biopsies taken at the same endoscopy. The diagnoses were provided to the researcher performing the biomarker candidate measurements to allow batch randomization design for the assay. Formalin-fixed, paraffinembedded (FFPE) tissue sections from the Ochsner Health System were selected and shipped to Brisbane, Australia for immunohistochemistry.
Both PROBE-NET and the Ochsner cohort provided information on patients' age, sex and body mass index (BMI, calculated as weight (kg) / [height (m)] 2 ); whereas ethnicity was provided by the Ochsner cohort only and education, alcohol drinking and tobacco smoking was only available in the PROBE-NET cohort. Data on demographics and lifestyle factors were compared among different clinical and histological groups using Pearson's chi-square test or Fisher's exact test as appropriate. P < 0.05 was considered to be statistically significant. Analyses were performed using SAS 9.4 software.
Lectin magnetic bead array (LeMBA) and multiple reaction monitoring (MRM)-mass spectrometry
AAL (Aleuria aurantia lectin), EPHA (erythroagglutinin from Phaseolus vulgaris), JAC (jacalin from Artocarpus integrifolia), and NPL (Narcissus pseudonarcissus lectin) (Vector Laboratories, Burlingame, CA) were individually conjugated to MyOne tosyl-activated Dynabeads® (Life Technologies) as previously described (20) . Total serum protein concentration was measured using bicinchoninic acid (BCA) assay (Pierce) (23) . 50 μg of serum protein samples were spiked with chicken ovalbumin as an internal standard and were denatured as described previously (22) . LeMBA pull-downs were performed using Bravo liquid handler (Agilent Technologies). The Bravo protocol and device files are available in supplemental method. The pull-down proteins were digested into peptides by on-bead enzymatic treatment with protease trypsin at 37°C for overnight (Modified sequencing grade trypsin from Promega, Madison, WI), vacuum-dried, and stored at -80 °C. The dried peptide samples were reconstituted in 0.1% formic acid, and then a mixture of ten synthetic stable isotope standard (SIS) labelled peptide was spikedinto the sample. The concentration of each of these ten SIS peptides was optimized so that their The precursor ions and transitions were selected based on discovery experiments described earlier (22) and through in silico analysis using Skyline (24) . The list of transitions containing precursor m/z, product m/z, collision energy, retention time, and delta retention time for PROBE-NET and Ochsner cohorts are reported in Supplemental Table 1 . The UHPLC system consisted of a reverse phase AdvanceBio Peptide Mapping column (150 × 2.1 mm i.d., 2.7 μm, #653750-902, Agilent Technologies) with a 5 mm long guard column. Mobile phase A was 0.1% formic acid, and mobile phase B was 100% acetonitrile containing 0.1% formic acid. The UHPLC system was operated at a flow rate of 0.4 mL/min at 60 °C. The gradient used for peptide separation was as follows: 3% B at 0 min; 35% B at 40 min; 95% B at 40.5 min; 95% B at 44.5 min; 3% B at 45 min; followed by conditioning of column for 4 min at 3% B. Skyline (version 3.6.0.10493) was used for inspecting and processing MRM data (24) . Poor quality peptides that showed non-reproducible results [% coefficient of variation (% CV) < 30%] for repeatedly processed QC serum sample were removed. Peak picking algorithm in Skyline was optimized for improved peak integration. Peak area for each peptide (sum of all transitions) was exported. The quality of acquired datasets ( Supplemental Table 2A for PROBE-NET cohort and Supplemental Table 2B for Ochsner cohort) were evaluated by % CV of spiked-in stable isotopelabeled internal standard (SIS) peptides and peptides derived from the spiked-in internal standard protein chicken ovalbumin. The data were normalized using the median intensity of 8 SIS peptides.
Peptide intensities were converted into protein intensity with Pearson correlation coefficient cutoff set at 0.6 (22) . As recently highlighted by others (25), this step serves as quality control for peptide level measurements resulting in a robust protein level quantitative dataset for down-stream statistical analysis. The normalized protein intensities were transformed using the natural logarithm and z-scores were calculated to ensure that there were no scale differences between the two datasets prior to downstream statistical analysis.
Statistical analysis
JMP Pro 13.2 (SAS Institute, Inc., Cary, NC, USA) was used for univariate and multivariate biomarker statistical analyses. Univariate logistic regressions were conducted on EAC vs NSE outcome, EAC vs BE outcome, and the surveillance outcome (BE-HGD or EAC vs BE or BE-ID or BE-LGD), against each of the glycoprotein_lectin biomarker candidates. Odds ratios (ORs) with 95% Wald confidence intervals (95% CIs), area under receiver operating characteristic curves (AUROCs) and Likelihood Ratio P values were calculated for both PROBE-NET and Ochsner cohorts. Recursive partitioning (also known as Classification and Regression Trees, CART) was used to identify a multivariate panel of markers that would discriminate between surveillance outcomes (BE-HGD+EAC vs BE+BE-ID+BE-LGD). The PROBE-NET dataset was used as the training set to develop predictive models, and the Ochsner dataset was used as the validation set. The set of 217 markers that were available in both PROBE-NET and Ochsner datasets was used in the training set, as well as baseline characteristics, including age, gender, and BMI. To avoid overfitting, models were limited to 6, 8, and 10 biomarker candidates. We also implemented a permutation test to assess the performance of the model fitting approach in the training set. Specifically, we fit our model to the training set using 5-fold cross-validation and noted the AUROC. Then we randomly permuted the response variable (EAC status) and refit a new model in exactly the same way and recorded the permutated AUROC. We repeated this procedure for 10,000 permutations to build a distribution of AUROCs against which we evaluated our observed AUROC. Thus models that tend to overfit the data lead to large AUROCs in the permutations relative to the observed AUROC thus allowing us to tune our models to avoid overfitting. The prediction formulas derived from PROBE-NET were then applied to the Ochsner dataset to determine sensitivity and specificity in the validation set.
Expression and purification of recombinant C9
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RESULTS
Workflow of this study is depicted in Figure 1B . We took a sequential approach to discover and validate serum diagnostic glycoprotein biomarker candidates. In previous study (22) , we discovered candidates that differentiate between EAC from NSE and BE groups. In this study, we first validate the biomarker candidates for EAC in two independent cohorts. As BE-HGD is expected to be an intermediate phenotype progressing towards EAC, next, we evaluated ability of the biomarker candidates to aid current surveillance program i.e. distinguish between patients who require follow-up endoscopy (BE-HGD and EAC) and those who do not (BE, BE-ID and BE-
LGD). Table 1 details the baseline demographic and clinical characteristics of the Australian (PROBE-NET) and Ochsner cohorts. Serum glycoprotein biomarker candidates were measured using our previously reported lectin magnetic bead array (20, 21)-coupled multiple reaction monitoring (MRM) mass spectrometry assay (26). In this method, lectin binding is used to isolate glycoproteins with particular glycan structures. Based on our previous work for BE/EAC (22, 27) , four lectins were selected for the independent validation cohorts, namely AAL, EPHA, JAC, and NPL. The targeted proteomics workflow uses a tier 3 assay with inclusion of internal standard peptides for 8 candidates. As compared to previously published MRM-MS assay that analyzed 41 glycoprotein candidates (22) , ~40 more target proteins were added to the assay (Supplemental Table 1 ). The uniqueness of target peptides was established using Skyline with human proteome as a background. The assay reproducibility was tested as described earlier (22) . PROBE-NET and Ochsner cohorts were independently analyzed with block randomization design for each cohort.
Univariate analysis of the PROBE-NET cohort dataset revealed 46 and 54 biomarker candidates with P<0.05 for EAC vs NSE and EAC vs BE comparisons respectively (Supplemental Table 3 ). Data for the top 10 biomarker candidates that differentiate EAC from NSE, and EAC from BE in PROBE-NET cohort are shown in Figure 2A and 2B, respectively. Out of these candidates, 16 candidates for EAC vs NSE comparison and 9 candidates for EAC vs BE comparison were also significantly different in the Ochsner cohort, confirming these glycoproteins as validated biomarker candidates. As illustrated in Figure 2C Next we considered BMI as a potential confounding factor for EAC biomarker validation.
Correlation analysis between BMI and biomarker candidate levels in all PROBE-NET samples revealed no substantial correlation (|r|<0.6) (Supplemental Table 4 ), although three proteins namely complement C3 (C3), C4b-binding protein alpha chain (C4BPA), and complement factor I (CFI) with multiple lectin pull-downs showed positive correlations with BMI in NSE patients only (|r| 0.6234-0.7069). Importantly, none of the top 10 biomarker candidates showed strong correlation with BMI. This suggests that top glycoprotein biomarker candidates measured using our workflow are not affected by a common confounding covariate, BMI.
Biomarkers for BE surveillance
Having confirmed univariate biomarkers for detection of EAC from NSE and BE in independent cohorts, we next evaluated the ability of serum glycoproteins to be used as a surveillance tool for BE and BE-LGD patients, i.e. to distinguish between patients who require treatment (BE-HGD and EAC) and those who do not (BE, BE-ID and BE-LGD). Eight biomarker candidates that showed AUROC > 0.6 in a BE surveillance setting for both PROBE-NET and Ochsner cohort (Figure 3 , Supplemental Table 3 ), comprised of GSN measured in AAL, NPL, and JAC pull-downs, C9 measured in JAC and EPHA pull-downs, AAL-binding PON1, AAL-binding PON3, as well as EPHA-binding Complement factor B (CFB).
Next we sought to generate a multimarker panel for BE surveillance, using the PROBE-NET cohort for modeling and Ochsner cohort for model validation. The minimal panel of six biomarker candidates showed 0.83 AUROC, 83% sensitivity and 69% specificity for the PROBE-NET cohort, and a moderate sensitivity of 61% and specificity of 65% for the Ochsner cohort (Table 2) . Addition of 4 more biomarker candidates to the panel increased the AUROC to 0.93, and improved the specificity and sensitivity measures for PROBE-NET, as well as the specificity for Ochsner cohort (Table 2) showed sensitivity of 71% and specificity of 77% to distinguish between the two groups. The performance of multimarker panel in a subset of treatment naïve Ochsner cohort is similar, if not slightly improved, as compared to results obtained using all available Ochsner cohort samples.
Complement C9 expression in BE and EAC tissue
In agreement with our previous finding of complement pathway dysregulation in EAC pathogenesis (22) , 5 of the 10 glycoprotein biomarker candidates in the final surveillance biomarker panel (Table 2) belonged to the complement pathway. As a first step to evaluate alterations of the complement pathway in EAC at a tissue level, we optimized immunohistochemistry staining for the top candidate, complement C9. Staining specificity of the method was confirmed by neutralization of the antibody with recombinant C9 protein prior to staining. In Supplemental Figure 1 , the disappearance of dark brown tissue staining after preincubation of anti-C9 antibody with recombinant C9 indicates the antibody specificity. We then evaluated expression of C9 in esophageal tissue sections from a subset of the Ochsner cohort. As shown in Figure 4A , the adjacent normal squamous epithelium tissue showed no or minimal C9 staining as compared to light to dark brown staining that was detected in BE and EAC. Dysplastic BE showed particularly strong staining in the plasma membrane and/or cytoplasm ( Figure 4A ).
Strong staining in immune infiltrates served as an expected positive control. Quantitation of staining intensity score against the tissue phenotype ( Figure 4B ) showed statistically significant association between C9 expression levels and histology groups of squamous epithelium, columnar by guest on November 18, 2018 http://www.mcponline.org/ Downloaded from epithelium, Barrett's mucosa, dysplasia/EAC (P<0.001). Specifically, 87% of the squamous epithelium showed no C9 staining as compared to all of the BE, dysplastic, or EAC tissue that showed some degree of C9 presence. In addition, 87% of BE and 67% dysplastic/EAC observations were positive for C9 with scoring intensity ≥2. In contrast, none of the squamous epithelia were stained strongly (intensity ≥2) for C9. Columnar epithelium with no evidence of intestinal metaplasia showed intermediate C9 staining. These novel data demonstrating elevated C9 protein in Barrett's and EAC cells provides some biological basis, to the use of elevated serum C9 as a biomarker candidate. The exact correlation between tissue and serum C9 remains to be established.
Serum complement C9 in progressor samples
As an additional evaluation, we examined C9 lectin pull-down levels in samples from PROBE-NET participants who had progressed from BE to BE-LGD (N = 4), BE-LGD to BE-HGD (N = 3), BE to BE-HGD (N = 1), BE to EAC (N = 1), and NSE to gastric type mucosa (N = 1) phenotype during follow-up. The progression time varied from 110 days up to 5 years.
Significant elevation of C9_EPHA and C9_NPL was observed following progression in this small patient cohort ( Figure 5 ).
DISCUSSION
This study progresses our previous serum glycoprotein research (22, 27) towards developing cost-effective EAC surveillance by validating serum biomarker candidates in two independent cohorts. Over the years, several studies have been carried out to identify circulatory biomarker candidates to diagnose BE-dysplasia-EAC disease spectrum (19, 28) . These studies have explored genetic alterations in cell free circulating DNA (29) , serum miRNA changes (30), circulating tumor cells (31) , glycan profile alteration in serum (32, 33) , circulatory autoantibodies (against cancer antigens) (34), volatile organic compounds found in breath analysis (35) , metabolic changes in urine (36) , and a panel of serum proteins (37) as promising diagnostic biomarker candidates for BE and/or EAC. However, none of these biomarker candidates have progressed from bench to bedside, likely due to the lack of subsequent validation studies in large independent cohort of patients. Here, we have addressed this gap by validating eight serum glycoprotein biomarkers for EAC in two independent patient cohorts including dysplastic samples.
In addition to demonstrating the robustness of our mass spectrometry based glycoproteincentric proteomics workflow for biomarker validation, the current study confirmed our previous finding of complement activation in EAC (22) . The complement system consists of a cascade of circulating proteases that are locally activated leading to the formation of the membrane attack complex on the immunogen and recruitment of phagocytes. Complement components are predominantly expressed and secreted into the plasma by the liver but are also found to be expressed in other tissues (38), including tumor cells (39) . While complement components are primarily involved in mediating innate immune response, recent studies have revealed an apparently paradoxical tumor-promoting role of the complement system (39, 40) . Complement C3 has been reported to play an autocrine role in ovarian and lung cancer tumor growth (41). C5a is elevated in serum of lung cancer patients (42) and increases the invasiveness of C5aR+ tumors (43) . Recently, Franc and colleagues found 15 co-occurring serum C9 proteoforms based on glycan expression profiling (44). Specifically, fucosylated C9 was reported to be elevated in the serum of lung cancer patients (45) .
Two previous publications reported on complement component changes in BE and EAC.
Bobryshev et al. reported reduced C1q expression in dendritic cells and macrophages in the epithelium of BE and EAC, and suggest this to be an immune-escape mechanism (46) . Song et al.
identified complement pathway proteins, complement C3 and complement C1r subcomponent to be increased in serum collected from BE-HGD and EAC patients respectively as compared to disease free individuals (47). The current study is the first to report C9 protein expression in BE and EAC cells, as demonstrated on tissue sections. In addition to validating our previous finding of elevated circulating C9 in LeMBA pull-downs in EAC, we also evaluated the utility of serum C9_JAC and C9_EPHA for BE surveillance in independent cohorts. Together, our results suggest a pathological change in the secretion, glycosylation, or expression of C9 during the progression of BE to BE-HGD/EAC. Modulation of C9 expression is unlikely to be the mechanism, since we detected strong C9 staining in both BE and BE-HGD tissue. Interestingly, bile (deoxycholic acid) treatment was reported to alter glycosylation and Golgi structure in esophageal epithelial and BE cells, resulting in impaired protein secretion via the classical pathway (48) . Hence, C9 may be sequentially regulated by expression level and glycosylation/secretion during BE-EAC progression. Further studies are required to determine the precise molecular changes in serum C9 with respect to normal-BE-dysplasia-EAC spectrum.
The strengths of this study include the validation of biomarker candidates in independent cohorts, evaluation of biomarker panel for BE surveillance, and the use of immunohistochemistry to determine the cellular origin of the top serum glycoprotein biomarker candidate. There are several limitations to our study. While our glycoprotein biomarker pipeline allows high-throughput glycoprotein biomarker discovery and validation, changes in the glycosylation site occupancy or glycan structural changes for the biomarker candidate are not determined. Furthermore, the functional consequences, if any, of these glycosylation changes in cancer progression also remain to be evaluated. The tier 3 mass spectrometry assay employed in our work may suit early stage validation studies but the final biomarker panel should be evaluated with tier 1 MRM-MS assay (or similar other assay platform) that allows absolute quantification. The small number of progressor samples available is a limitation, not only for the current study, but for evaluation of BE/EAC biomarkers in general. International collaborations and longitudinal cohort sampling are therefore required to advance the search for EAC biomarkers. Finally, the tissue expression of C9 and other candidates also need to be confirmed in a larger number of samples.
In summary, we have validated a number of serum glycoprotein biomarkers that warrant further clinical testing in large independent cohorts including longitudinal patient samples. Further evaluation and development of these biomarkers to a blood test may aid the current endoscopybiopsy surveillance program of BE patients for early detection of dysplastic progression. 
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